Alteogen Inc.
196170
Rang in aandelen
#1894
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Aandeelprijs
$159.04
Marktkapitalisatie
$11.07B
Verandering (1 dag)
-2.95%
Verandering (1 jaar)
-48.94%
Land
KR
Handel Alteogen Inc. (196170)
Categorie
Healthcare
Operationele marge voor Alteogen Inc. (196170)
Operationele marge op October 2026 TTM: 47.16%
Volgens de meest recente financiële rapporten en aandelenkoers van Alteogen Inc. is de huidige operationele marge (TTM) 47.16%. Eind 2023 had het bedrijf een operationele marge van -10.09%.
Geschiedenis van de operationele marge van Alteogen Inc. van 2012 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 47.16% | 90.93% |
| 2024 | 24.70% | -344.80% |
| 2023 | -10.09% | -90.10% |
| 2022 | -101.97% | 160.06% |
| 2021 | -39.21% | 27,907.14% |
| 2020 | -0.14% | -98.18% |
| 2019 | -7.70% | -86.23% |
| 2018 | -55.90% | 9.61% |
| 2017 | -51.00% | -35.50% |
| 2016 | -79.07% | -3,117.94% |
| 2015 | 2.62% | -74.51% |
| 2014 | 10.28% | -62.39% |
| 2013 | 27.33% | -34.80% |
| 2012 | 41.92% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -99.18% |
US
|
|
| -149.01% | -103.16% |
US
|
|
| 25.57% | -99.46% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.39% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.